| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Internal Medicine III,* Division of Rheumatology, and the Institute of Biological Sciences, University of Vienna, Vienna, Austria; the Center of Molecular Medicine,¶ Austrian Academy of Sciences, Vienna, Austria; the Department of Pathology, Amgen, Incorporated, Thousand Oaks, California; and the Molecular Genetics Laboratory, Institute of Immunology, Alexander Fleming Biomedical Sciences Research Center, Vari, Greece
Local bone erosion and systemic bone loss are hallmarks of rheumatoid arthritis and cause progressive disability. Tumor necrosis factor (TNF) is a key mediator of arthritis and acts catabolically on bone by stimulating bone resorption and inhibiting bone formation. We hypothesized that the concerted action of anti-TNF, which reduces inflammation and parathyroid hormone (PTH), which stimulates bone formation, or osteoprotegerin (OPG), which blocks bone resorption and could lead to repair of local bone erosions and reversal of systemic bone loss. To test this, human TNF-transgenic mice with established erosive arthritis and systemic bone loss were treated with PTH, OPG, and anti-TNF, alone or in combination. Local bone erosions almost fully regressed, on combined treatment with anti-TNF and PTH and/or OPG, suggesting repair of inflammatory skeletal lesions. In contrast, OPG and anti-TNF alone led to arrest of bone erosions but did not achieve repair. Treatment with PTH alone had no influence on the progression of bone erosions. Local bone erosions all showed signs of new bone formation such as the presence of osteoblasts, osteoid formation, and mineralization. Furthermore, systemic bone loss was completely reversed on combined treatment and this effect was mediated by osteoblast stimulation and osteoclast blockade. In summary, we conclude that local joint destruction and systemic inflammatory bone loss because of TNF can regress and that repair requires a combined approach by reducing inflammation, blocking bone resorption, or stimulating bone formation.
This article has been cited by other articles:
 |
|
 |
|
  M. Ohishi, R. Chiusaroli, M. Ominsky, F. Asuncion, C. Thomas, R. Khatri, P. Kostenuik, and E. Schipani Osteoprotegerin Abrogated Cortical Porosity and Bone Marrow Fibrosis in a Mouse Model of Constitutive Activation of the PTH/PTHrP Receptor Am. J. Pathol., June 1, 2009; 174(6): 2160 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Gengenbacher, H-J Sebald, P M Villiger, W Hofstetter, and M Seitz Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis Ann Rheum Dis, May 1, 2008; 67(5): 620 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ochi, M. Shinohara, K. Sato, H.-J. Gober, T. Koga, T. Kodama, T. Takai, N. Miyasaka, and H. Takayanagi Pathological role of osteoclast costimulation in arthritis-induced bone loss PNAS, July 3, 2007; 104(27): 11394 - 11399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Iqbal, L. Sun, T. R. Kumar, H. C. Blair, and M. Zaidi Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation PNAS, October 3, 2006; 103(40): 14925 - 14930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Jimenez-Boj, K. Redlich, B. Turk, B. Hanslik-Schnabel, A. Wanivenhaus, A. Chott, J. S. Smolen, and G. Schett Interaction between Synovial Inflammatory Tissue and Bone Marrow in Rheumatoid Arthritis J. Immunol., August 15, 2005; 175(4): 2579 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Morony, K. Warmington, S. Adamu, F. Asuncion, Z. Geng, M. Grisanti, H. L. Tan, C. Capparelli, C. Starnes, B. Weimann, et al. The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy Endocrinology, August 1, 2005; 146(8): 3235 - 3243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Simonini, T. Giani, S. Stagi, M. de Martino, and F. Falcini Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis Rheumatology, June 1, 2005; 44(6): 777 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hayer, G. Steiner, B. Gortz, E. Reiter, M. Tohidast-Akrad, M. Amling, O. Hoffmann, K. Redlich, J. Zwerina, K. Skriner, et al. CD44 is a determinant of inflammatory bone loss J. Exp. Med., March 21, 2005; 201(6): 903 - 914. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
